The Journal of Toxicological Sciences
Online ISSN : 1880-3989
Print ISSN : 0388-1350
ISSN-L : 0388-1350
Original Article
Genotoxicity studies of ubidecarenone (coenzyme Q10) manufactured by bacteria fermentation
Noriko YamaguchiKaori NakamuraYoshihiro OgumaSho FujiwaraMichihito TakabeAkira SonoTsuneshirou KawasakiKazumasa OtsuboKoichi Wakigawa
Author information
JOURNAL FREE ACCESS

2009 Volume 34 Issue 4 Pages 389-397

Details
Abstract

Ubidecarenone (coenzyme Q10) has been widely used as a complementary therapy in heart failure and as a dietary supplement for over two decades. Ubidecarenone is manufactured by organic synthesis, yeast (non-Saccharomyces cerevisiae) fermentation, or bacteria fermentation. There are many reports on the safety of ubidecarenone. However, genotoxicity of ubidecarenone manufactured by bacteria fermentation has not been reported. We carried out genotoxicity evaluation of ubidecarenone manufactured by bacteria fermentation through the bacterial reverse mutation test (Ames test) and in vitro chromosome aberration test in compliance with the Japanese guidelines on genotoxicity testing of pharmaceuticals and the Organization for Economic Co-operation and Development (OECD) guidelines for testing chemicals. The results indicate neither increase of revertant colonies nor chromosome aberration, suggesting that the ubidecarenone manufactured by bacteria fermentation has no genotoxic activities under the condition of this study.

Content from these authors
© 2009 The Japanese Society of Toxicology
Previous article Next article
feedback
Top